Foghorn Therapeutics, Inc. (FHTX)
1.87
+0.02
(+1.08%)
USD |
NASDAQ |
Oct 19, 15:05
Foghorn Therapeutics Profit Margin (Quarterly) : -44.74% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.74% |
| March 31, 2026 | -608.4% |
| December 31, 2025 | -234.3% |
| September 30, 2025 | -194.4% |
| June 30, 2025 | -237.3% |
| March 31, 2025 | -316.4% |
| December 31, 2024 | -682.9% |
| September 30, 2024 | -244.9% |
| June 30, 2024 | -333.6% |
| March 31, 2024 | -495.4% |
| December 31, 2023 | -417.9% |
| September 30, 2023 | -82.07% |
| Date | Value |
|---|---|
| June 30, 2023 | -526.6% |
| March 31, 2023 | -574.3% |
| December 31, 2022 | -690.4% |
| September 30, 2022 | -388.4% |
| June 30, 2022 | -608.3% |
| March 31, 2022 | -686.6% |
| December 31, 2021 | -4.09K% |
| September 30, 2021 | -63.61K% |
| June 30, 2021 | -8.28K% |
| March 31, 2021 | -8.04K% |
| December 31, 2020 | -8.27K% |
| September 30, 2020 | -10.26K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -25.80% |
| Gross Profit Margin (Quarterly) | 98.76% |
| Operating Margin (Quarterly) | -54.78% |
| Return on Net Operating Assets | -238.2% |